Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
140 Cards in this Set
- Front
- Back
cells
|
the basic unit that makes up tissues
|
|
tissues
|
a group of different cell types that combine to form a specific function
|
|
organs
|
fully differentiated body parts with specialized functions
|
|
organ systems
|
organs combined make up
|
|
plasma membrane
|
the barrier of the cellular structure is called the
|
|
cytoplasm
|
surrounds the nucleus
|
|
organelles
|
each of the _______ perform a specific function
|
|
endoplasmic reticulum
|
organelle that is the cell transport system
|
|
Golgi apparatus
|
organelle responsible for protein packaging
|
|
lysosome
|
organelle responsible for digestion
|
|
peroxisome
|
organelle that breaks down fatty acids
|
|
proteosome
|
organelle that breaks down protein
|
|
mitochondria
|
organelle responsible for the energy in the cell
|
|
nucleus
|
organelle that contains the DNA
|
|
cytoskeleton
|
organelle that contributes to the cell shape
|
|
trasportation
|
cellular function: movement in and out of the cell
|
|
ingestion
|
cellular function: take in substances for use
|
|
secretion
|
cellular function: release items
|
|
respiration
|
cellular function: produce ATP
|
|
communication
|
cellular function: react with other items
|
|
reproduction
|
cellular function: grow and divide
|
|
passive transport
|
a transport mechanism that require minimal energy
|
|
diffusion
|
a type of passive transport: high to low concentration
|
|
osmosis
|
a type of passive transport: movement of water
|
|
facilitated diffusion
|
a type of passive transport: utilization of transport proteins
|
|
active transport
|
a type of transport mechanism that requires energy
|
|
endocytosis
|
process used to transport large substances into the cell
|
|
pinocytosis
|
type of endocytosis: ATP requiring process of ingesting small vesicles
|
|
phagocytosis
|
type of endocytosis: process of ingesting large particles such as cells, bacteria, and damaged cellular components resulting in the release of oxygen free radicals
|
|
secretion
|
cellular products packaged into vesicles; transport out of the cell by exocytosis
|
|
respiration
|
use of oxygen to produce energy; energy produced by mitochondria
|
|
communication
|
signals between cells controlling cellular function and behavior
|
|
receptor- ligand
|
In cellular communication, messages are communicated by ____________ binding.
|
|
cellular damage
|
In cellular communication, feedback mechanisms prevent ________ _________.
|
|
reproduction
|
cellular division under genetic control
|
|
mitosis
|
In reproduction, _______ produces an exact replica.
|
|
meiosis
|
In reproduction, _______ produces a cell that has 1/2 chromosome of each parent cell
|
|
differentiation
|
In reproduction, cellular ________ directs the development if specific cell types.
|
|
atrophy
|
Cellular response to stress:
decrease in size |
|
hypertrophy
|
Cellular response to stress:
increase in size |
|
hyperplasia
|
Cellular response to stress:
increase in number of cells |
|
metaplasia
|
Cellular response to stress:
change from one type to another |
|
dysplasia
|
Cellular response to stress:
change in cell size, shape, uniformity, arrangement, and structure |
|
1. physical
2. mechanical 3. thermal R/T extremes in temperature 4. chemical |
Causes of cellular injury:
1. 2. 3. 4. |
|
apoptosis
|
Mechanisms cellular of death:
cellular suicide that replaces old cells with new ones |
|
necrosis
|
Mechanism of cellular death:
disorderly proces associated with inflammation |
|
cerebral atrophy
|
reduction in the size of the cells in the cerebrum of the brain; includes progressive reduction in the size of neurons
|
|
1. reduced stimulation
2. injury (decreased perfusion) |
Cerebral atrophy is a result of:
1. 2. |
|
focal
|
Cerebral Atrophy Clinical Manifestations:
localized to one region |
|
global
|
Cerebral Atrophy Clinical Manifestations:
affecting the entire brain |
|
1. function
2. neurologic 3. MRI |
Cerebral Atrophy Diagnostic Criteria:
1. Early identification of loss of ______ 2. _________ examination 3. Imaging studies such as a _______ |
|
2. injury
3. disease |
Cerebral Atrophy Treatment:
1. Prevention 2. Interruption of ______ process 3. Slowing course of ________ |
|
Cardiac Hypertrophy
|
increased cardiac muscle mass
|
|
1. workload
2. functional 3. genetic |
Cardiac Hypertrophy Etiology:
1. Excessive cardiac _________ 2. Increased ________ demand 3. Inherited ______ trait |
|
non- sex
|
PRIMARY Cardiac Hypertrophy:
Inherited _______- _____ linked genetic trait |
|
1. left ventricular
2. myocardial |
SECONDARY Cardiac Hypertrophy:
1. Due to an underlying condition increasing _____ __________ workload 2. Increasing in left ventricular muscle mass results from an increase in ___________ cell size. |
|
1. mild to severe
2. shortness of breath 3. syncope 4. impaired cardiac function |
Cardiac Hypertrophy Clinical Manifestations:
1. 2. 3. 4. |
|
1. genetic
3. exercise 4. arrhythmia 5. murmur |
Cardiac Hypertrophy Diagnostic Material:
1. ______ testing 2. hypertension 3. reduced ________ tolerance 4. ventricular ________ 5. heart ________ |
|
ventricular arrhythmia
|
altered signals in the cells of the ventricle
|
|
1. surgical
2. pharmacologic 3. non-pharmacologic |
Cardiac Hypertrophy Treatment:
1. 2. 3. |
|
1. ventricles
2. pressure |
Pharmacologic Cardiac Hypertrophy Treatment:
1. Drugs that relax the _________ 2. Drugs that reduce the workload of the heart - decrease the _______ that the heart must pump against |
|
restriction
|
Non-pharmacologic treatments for Cardiac Hypertrophy includes activity ________.
|
|
Acromegaly
|
condition of cellular hyperplasia
|
|
Acromegaly
|
this results from excessive hormonal stimulation of pituitary growth hormone and liver insulin like growth factor.
|
|
Acromegaly
|
______ leads to excessive growth in bones, cartilage, soft tissues, and organs.
|
|
Acromegaly
|
______ occurs after epiphyseal plate closure ( gigantism if occurs prior to closure of epiphyseal plate)
|
|
1. swelling
2. facial 3. hands 4. deepening 6. skin 7. reproductive |
Acromegaly Clinical Manifestations:
1. soft tissue ______ 2. altered ______ features 3. pain and numbness in ______ 4. voice _______ 5. snoring 6. ______ changes 7. altered ______ function |
|
- Glucose tolerance test
- Growth hormone - IGF-1 |
Acromegaly Diagnostic Criteria:
1. History and physical examination 2. Laboratory analysis - - - |
|
growth
|
Acromegaly Pharmacologic Treatment:
drugs to reduce _________ hormone secretion |
|
promote death in growth hormone hyper-secreating cells
|
Acromegaly Non-Pharmacologic Treatment:
radiation therapy to |
|
hypersecretion
|
Acromegaly Surgical Treatment:
removal of tumor causing ________ of growth hormone |
|
Cervical Metaplasia and Dysplasia
|
cellular adaptation of the squamous and columnar epithelial cells in the transformation zone of the cervix
|
|
Metaplasia
|
changing of cell types as a response to environmental stressors
|
|
Dysplasia
|
abnormal growth and disordered differentiation in dividing cells
|
|
1. sexual activity
3. HPV |
No signs and symptoms of Cervical Metaplasia and Dysplasia but, risk factors include:
1. early onset of ______ _______ 2. Multiple partners 3. exposure to _____ 4. smoking |
|
2. zone
HPV 3. cervical |
Cervical Metaplasia and Dysplasia Diagnostic Criteria:
1. history and physical exams 2. Screening tests - Micro exam of transformation _____ cells - _______ screening 3. Diagnostic test - Biopsy of ______ tissue |
|
1. risk
2. - cold - surgical |
Cervical Metaplasia and Dysplasia Treatment:
1. ______ reduction 2. elimination of _____ cells - _____ therapy - _____ excision |
|
environmental
|
Exposure to ______ chemicals leads to cardiovascular cell injury.
|
|
oxidative damage
inflammation |
Airborne particulate matter causes ______ _____ and _______ in heart and blood vessel cells.
|
|
aortic, lung, coronary
|
Environmental Toxins and Cardio. Disease Clinical Manifestations:
______ aneurysm, chronic ______ disease, cancer, pneumonia, ______ heart disease, stroke |
|
CV
|
Environmental Toxins and Cardio. Disease Diagnostic Criteria:
1. history and physical exam 2. lab studies: for markers of ___ disease |
|
exercise, increased, cardiac
|
Environmental Toxins and Cardio. Disease Complications:
reduced _____ tolerance, difficulty breathing, blood clot, hypertension, _____ heart rate, reduced _____ output, hyperlipidemia |
|
1. risk
2. symptom 3. smoking cessation and management of CV complications |
Environmental Toxins and Cardio. Disease Treatment:
1. ____ reduction 2. ______ management 3. pharmacologic treatment: drugs that assist with |
|
inflammation
|
nonspecific process triggered by tissue injury
|
|
blood flow
|
Goal of inflammation:
increase _____ _____ to site (vascular response) |
|
healing cells
|
Goal of inflammation:
increase ______ _____ at site (cellular response) |
|
injured
tissue repair |
Goal of inflammation:
remove _______ tissue & prepare for _______ _______ |
|
skin and mucous membrane
|
the first line of defense
|
|
inflammatory response
|
the second line of defense
|
|
immune response
|
the third line of defense
|
|
vascular response
|
facilitated by chemical mediators
|
|
vascular response
|
induces vasodilation (increases blood flow) and increases capillary permeability (easier movement of particles)
|
|
vascular response
|
objective is to get more blood flowing to the injured area
|
|
1. WBC
2. platelets 3. endothelial or damaged tissue cells |
Cell-derived Inflammatory Mediators
1. 2. 3. |
|
1. Complement system
2. Kinin system 3. Clotting system |
Plasma-derived Inflammatory Mediators
1. 2. 3. |
|
1. chemotaxis
2. cellular adherence 3. cellular migration |
3 steps of cellular response:
1. 2. 3. |
|
Local manifestations
|
_____ ________ include heat, incapacitation, pain, edema, redness
|
|
systematic manifestations
|
______ _______ may include fever (pyrexia), fatigues, weight loss, headache, lethargy, increased circulating leukocytes, and plasma proteins.
|
|
- bood flow
- decrease - chemical mediators |
Treatment of Inflammation:
- reduce _____ _____ - _______ swelling - block the action of ______ _______ |
|
1. Inflammatory phase
2. Proliferative phase 3. Remodeling phase |
Phases of Healing and Tissue Repair
1. 2. 3. |
|
chronic inflammation
|
recurrent or persistant inflammation lasting several weeks or longer
|
|
chronic inflammation
|
monocytes, macrophages, and lymphocytes more prominently involved
|
|
chronic inflammation
|
formation of granulomas and scarring often occur
|
|
1. Infection
2. Ulceration (poor perfusion) 3. Dehiscence ( inadequate scar formation) 4. Keloids (hypertrophic scars) 5. Adhesions (abdominal surgery) |
Complications of Healing:
1. 2. 3. 4. 5. |
|
1. Burns
2. Rheumatoid Arthritis (RA) 3. Gastritis 4. Inflammatory Bowel Disease (IBS) |
Application of the Concepts of Inflammation:
1. 2. 3. 4. |
|
excessive heat
radiation caustic chemicals electricity |
The CAUSE OF BURNS is direct contact with __________, _______, ________, or ________.
|
|
acute inflammatory response
|
The RESULT OF BURNS is _________.
|
|
type and time
|
Burn severity is correlated with exposure ______ and _____.
|
|
superficial partial- thickness
|
Burn classification:
epidermis |
|
deep partial- thickness
|
Burn classification:
epidermis and some dermis |
|
full thickness
|
Burn classification:
epidermis, dermis, and maybe some SQ tissue |
|
2. function
3. blistering 4. full thickness |
Burn Clinical Manifestations:
1. heat, swelling, pain, redness 2. loss of _______ 3. _____ occurs with deep partial burns 4. redness, eschar, edema, exudate characterize _____ _______ burns. |
|
Nines
|
Burn Diagnostic Criteria includes the Rule of ______.
|
|
1. wound depth
2. surface area 3. required level of treatment |
American Burn Association has designated criteria for distinguishing minor, moderate, and major burns based on:
1. 2. 3. |
|
cool; rinse
|
Burn Treatment:
remove source of injury and _____ or _____ skin. |
|
breathing
|
Burn Treatment:
airway, _________, circulation |
|
nutrition; analgestics
|
Burn Treatment:
fluids, _______, antibiotics, _______ |
|
1. hydrotherapy
2. skin grafting |
Burn Treatment:
Wound management may include: 1. 2. |
|
1. genetic
2. immune triggering 3. autoimmunity |
Causes of RA-
1. _______ susceptibility 2. _______ ________ event 3. Development of ________ against synovial cells |
|
RA
|
Chronic inflammation of synovial membranes and synovial hyperplasia
|
|
1. genetic
2. Immune Triggering 3. autoimmunity |
Reasons for RA:
1. _________ susceptibility 2. ________ ________ event 3. Development of _________ against synovial cells |
|
2. symmetrical
3. stiffness 5. decreased |
RA clinical manifestations:
1. mild to debilitating 2. _______ joints 3. pain and _______ of joints 4. redness, heat, and swelling 5. ________ mobility |
|
ESR
CRP IgG ANA |
RA Diagnostic Criteria
-No definitive test -Increased likelihood with positive findings - erythrocyte sedimentation rate ( ) - C-reactive protein ( ) - Rheumatoid factor ( ) - Antinuclear antibodies ( ) |
|
1. drugs that induce remission
2. rest and activity 3. physical therapy |
RA Treatment:
1. Pharamcologic: ________________ Non- pharamcologic: 2. ______ and ______ balance 3. _________ __________ exercise 4. splints 5. surgery |
|
Acute Gastritis
|
ingestion of irritating substances and/or poor gastric perfusion results in acute inflammation of the gastric mucosa; gastric epithelial cell necrosis; gastric acid erodes underlying tissues
|
|
1. abdominal
3. appetite |
Acute Gastritis Clinical Manifestations:
1. mild to severe _________ pain 2. indigestion 3. loss of _________ 4. nausea 5. vomiting |
|
1. history and physical
2. endoscopic 3. stool 4. blood |
Acute Gastritis Diagnostic Criteria:
1. ________ and ________ exam 2. ___________ examination 3. _____ analysis to check for blood 4. complete ______ count to check for anemia |
|
1. irritating substance
2. buffer or decrease |
Acute Gastritis Treatment:
1. Discontinue ingestion of ____________ 2. _______ or ________ production of gastric acid |
|
Chronic Gastritis
|
chronic infection or autoimmune process leading to chronic inflammation; gastric epithelial and mucosal cell atrophy; gastric acid production impaired
|
|
2. appetite
4. asymptomatic |
Chronic Gastritis Clinical Manifestations:
1. dyspepsia 2. loss of _________ 3. vomiting 4. can be _________ |
|
1. endoscopic
2. gastric |
Chronic Gastritis Diagnostic Criteria:
1. __________ examination 2. biopsy of ________ tissue |
|
1. chronic infectious
2. Immunosuppressive |
Chronic Gastritis Treatment
1. Antibiotics for __________ ____________ processes 2. _______________ drugs for autoimmune processes |
|
Chron Disease
|
chronic inflammation anywhere throughout the GI tract but most commonly in small intestines; non- continuous penetrating ulcerations and fibrosis; impaired intestinal absorption and bowel obstruction can result
|
|
abdominal
diarrhea blood |
Crohn Disease Clinical Manifestations:
- ________ pain, non-bloody __________, malnutrition, hidden ________ in stool, fever, weight loss, and fatigue |
|
1. history and physical
2. endoscopic 3. blood |
Crohn's Disease Diagnostic Criteria
1. ________ and __________ exam 2. ___________ examination 3. complete _________ count |
|
1. symptom
2. pharmacologic 3. dietary 4. surgical |
Crohn Disease Treatment
1. ___________ management 2. ___________ treatment 3. ___________ changes 4. ___________ treatment |
|
Ulcerative Colitis
|
chronic inflammation begins in rectum and ascends the descending colon; continuous superficial areas of ulceration; perforation, obstruction, and massive hemorrhage can result
|
|
2. rectal
3. abdominal |
Ulcerative Colitis Clinical Manifestations:
1. diarrhea 2. ________ bleeding 3. ________ pain 4. fever 5. anemia |
|
1. history and physical
2. endoscopic 3. blood |
Ulcerative Colitis Diagnostic Criteria:
1. ________ and _________ exam 2. __________ examination 3. complete _________ count |
|
1. symptom
2. pharmacologic 3. dietary 4. surgical |
Ulcerative Colitis Treatment:
1. _________ management 2. _________ treatment 3. _________ changes 4. _________ treatment |